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Abstract
The direct reprogramming of human somatic cells to induced pluripotent stem cells (iPSCs) offers
exciting prospects for disease modelling and regenerative medicine. Several recent reports support
the feasibility of generating various blood cell types from iPSCs through in vitro-directed
differentiation. However, the derivation of hematopoietic stem cells (HSCs) capable of long-term
reconstitution of all hematopoietic lineages appears to be more challenging. These hurdles
notwithstanding, cell engineering strategies aiming to correct genetic defects at the stem cell level are
already emerging. Robust methodologies for the generation of definitive human HSCs conferring
high-level, multilineage, long-term, hematopoietic reconstitution thus are direly needed before the
therapeutic potential and safety of iPSC-derived cell products can be thoroughly investigated.
Introduction and context
In 2006, Takahashi and Yamanaka [1] reported the
direct reprogramming of mouse fibroblasts to pluri-
potent stem cells, which were termed induced pluripo-
tent stem cells (iPSCs). This scientific breakthrough was
achieved through overexpression of the four transcrip-
tion factors OCT4, SOX2, KLF4, and c-MYC [1]. The
successful reprogramming of human somatic cells
reported the following year [2-4] opened new frontiers
for disease modelling and regenerative medicine. Since
then, several methodologies, using viral, non-viral, or
chemical approaches, have been devised to establish
iPSCs from various mouse and human somatic cell
types [5]. These include mouse cells in all stages of the
hematopoietic hierarchy and human progenitor cells
from cord blood, bone marrow, and peripheral blood
[6-9]. It is now widely accepted that mouse and human
iPSCs possess morphological, molecular, and develop-
mental attributes that closely resemble those
of blastocyst-derived embryonic stem cells (ESCs),
although their global gene expression patterns and
epigenetic state may not be identical [5,10]. Directed
differentiation protocols already in use in ESCs were
promptly applied to iPSCs, yielding numerous cell
types, including neurons, cardiomyocytes, adipocytes,
and endothelial and hematopoietic cells.
However, the generation of human hematopoietic stem
cells (HSCs) conferring multilineage, long-term, hema-
topoietic reconstitution remains elusive. HSCs originate
in early embryonic development, after which they
expand and self-renew in successive anatomical loca-
tions. Hematopoiesis is initiated with the specification of
a subset of mesodermal cells known as hemangioblasts,
which yield both endothelial and hematopoietic pro-
geny. The first hemangioblasts arise in the primitive
streak of the embryo and then migrate to the yolk sac,
where they form blood islands [11]. The ensuing first
wave of hematopoiesis predominantly yields erythroid
cells, which express embryonic and fetal globins and
macrophages, but not lymphoid cells. The immediate
precursors of definitive HSCs are arterial endothelial cells
[12-15], which become HSCs capable of long-term
multilineage repopulation of adult hosts in the dorsal
aorta of the aorta-gonad-mesonephros (AGM) region
and the chorioallantoic vessels of the placenta. These
early CD34
+, c-kit
+, CD41
+ HSCs next migrate to the
placenta and mostly to the fetal liver, where their
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hematopoiesis shifts from liver to bone marrow, from
which most blood cells originate throughout the
organism’s adult life span.
Recent advances
In vitro generation of blood cell types from
ESCs and iPSCs
Hematopoietic lineage specification from pluripotent
cells is obtained in one of two general approaches, using
either embryoid body formation in the presence of
hematopoietic cytokines or co-culture with stromal cell
lines such as the OP9 stroma cell line. Several blood cell
types have been successfully generated from murine or
human ESCs. These include mouse and human B- and
T-lineage cells [16], megakaryocytes [17], and erythroid
cells. The latter have revealed that human ESC-derived
erythropoiesis closely mimics primitive erythropoiesis,
characterized by the expression of the embryonic e and z
and the fetal a and g globins [18,19]. The analysis of
globin gene expression in erythrocytes derived from
human iPSCs likewise revealed a pattern of primitive
erythropoiesis [20].
Derivation of HSCs from ECSs and iPSCs
The generation of self-renewing multipotent HSCs from
ESCs or iPSCs appears to be challenging. Several early
reports illustrated the difficulty of producing HSCs
capable of reconstituting adult, irradiated recipients
[21,22]. Intravenous injection of murine or human
ESC- and iPSC-derived hematopoietic cells resulted in
little or no engraftment [23-28]. More recent studies have
yielded more encouraging results. Ledran et al. [29]
reported that co-culture of human ESCs on primary AGM
stroma induced HSCs capable of primary and secondary
hematopoietic engraftment into nonobese diabetic/
severe combined immunodeficiency disease Il2rgc
null
(NOG) mice (0.11-16.26%). Furthermore, culture of
human ESCs and iPSCs with medium conditioned by
HepG2 cells, a human hepatocarcinoma cell line, was
shown to enhance the generation of mesodermal
derivatives, including hematopoietic cells, with the
ability to repopulate sublethally irradiated NOG mice
for almost 1 year [30].
Efforts to engineer functional adult HSCs from
ESCs or iPSCs
Attemptstoengineerdefinitivehematopoiesishavesofar
largely focused on HOX family members (particularly
HOXB4 and HOXA10), which are transcription factors
involved in the formation or maintenance of HSCs [11].
Ectopic expression of HOXB4 in mouse ESCs has been
reported to give rise to HSC-like cells capable of long-
term repopulation [31,32]. However, the in vivo
reconstitution obtained is strongly biased toward mye-
loid cells, hardly yielding lymphoid cells [32,33], while
continuous HOXB4 expression poses oncogenic risks
[34]. Cdx genes were also shown to promote the
specification of hematopoietic progenitors in mouse
ESCs [35]. However, these strategies have not been
successful toward the generation of engraftable HSCs
from human ESCs [25], highlighting the difficulty in
translating mouse ESC-based studies into human pluri-
potent stem cell engineering.
Several investigators have observed that globin switching
occurs in cultured human ESC-derived erythroid progeny
in a time-dependent fashion, although the underlying
mechanisms are not understood [18,19,36]. Fetal hema-
topoietic cells transplanted into adult sheep were
previously shown to switch over time [37]. It is therefore
possible that a prolonged in vitro culture or in vivo
maturation is needed for the generation of developmen-
tally mature erythroid progeny.
Implications for clinical practice
The advent of iPSCs holds great promise for regenerative
medicine. iPSC-based research is poised to enable a
watershed of knowledge on human cell development as
well as provide critical tools for disease modelling and
invitro drugscreening.Thepotentialfordevelopingnovel
cell therapies is equally tantalizing but still uncertain at
this time. Reprogramming technologies offer the pro-
spect of generating blood cell types on a patient-specific
basis. Thus, red blood cells could be generated for
individuals with severe congenital anemias or polytrans-
fused subjects who require a unique blood cell type.
A repertoire of naïve T lymphocytes could be generated
for subjects with acquired or congenital deficiencies or
aging subjects afflicted by immunosenescence. However,
the methods for generating such cell types are still in
their infancy and marred with considerable biological,
safety, and economic uncertainties. A holy grail for this
field is to generate HSCs, which would open new doors
for both disease correction and regenerative medicine.
Two recent proof-of-principle studies highlighted the
potential of combined gene and cell therapy with
autologous iPSCs to treat Fanconi anemia and sickle
cell disease [26,33]. Robust protocols for the directed
differentiation of human iPSCs to all hematopoietic cells
will provide valuable tools for modelling hematopoiesis
and hematological disorders, as exemplified in a recent
study on polycythemia vera [9]. However, as reviewed
above, there remain significant obstacles to the genera-
tion of adult HSCs capable of long-term, pan-lineage,
hematopoietic reconstitution. Further studies are also
required to assess the hematopoietic potential of human
iPSCs in comparison with that of ESCs [9,38-40]. Thus,
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tempered with patience as a considerably larger body
of basic investigation is needed to unravel the biological
and therapeutic potential as well as the safety profile of
iPSC-derived hematopoietic cell products.
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